Are Auto Stem Cell Transplants More Effective On Outpatient Basis?

A new study suggests that Autologous hematopoietic cell transplantations (Auto-HCT) could be more effective across a number of different measurements if performed on an outpatient basis, compared to an inpatient basis.

Auto-HCT has not traditionally been regarded as a procedure that is done on an outpatient basis. However, this appears to be changing, and more and more patients are undergoing the procedure and then going home. Researchers reporting in the journal Bone Marrow Transplantation decided to carry out a retrospective analysis and determine if one was better than the other.

Researchers from the Division of Hematology and Oncology, Medical College of Wisconsin in Milwaukee compared outcomes in 230 patients who underwent Auto-HCT either as inpatients or outpatients for either lymphoma or myeloma.

What they found included the following:

Median time to neutrophil recovery:

  • Outpatients: 10 days
  • Inpatients: 11 days

Median time to platelet recovery

  • Outpatients: 19 days
  • Inpatients: 20 days

Two-year progression free survival:

  • Outpatient: 62 percent
  • Inpatient: 54 percent

One and two year overall survival rates:

  • Outpatients: 97 percent and 83 percent
  • Inpatients: 91 percent and 80 percent

These data and others led them to conclude that "with daily outpatient evaluation and aggressive supportive care, outpatient Auto-HCT can result in excellent outcomes for myeloma and lymphoma patients."

Source: Bone Marrow Transplantation

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap